COMMUNIQUÉS West-GlobeNewswire

Cytokinetics to Participate in March Investor Conferences

03/03/2025 - 22:00

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor conferences in March: [...]

BioXcel Therapeutics Announces $14 Million Registered Direct Offering

03/03/2025 - 21:33

NEW HAVEN, Conn., March 03, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in [...]

Marius Pharmaceuticals Partners with Major Academic Medical Center on Education and Research Efforts for Oral Testosterone

03/03/2025 - 21:00

RALEIGH, N.C., March 03, 2025 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals , a pharmaceutical company dedicated to developing innovative therapies for testosterone deficiency, has partnered with Duke University School of [...]

Instinct Science Launches Standards of Care™: The Future of Veterinary Clinical Decision Support

03/03/2025 - 20:02

PHILADELPHIA, March 03, 2025 (GLOBE NEWSWIRE) -- Instinct Science, a leader in veterinary software innovation, announces the launch of Standards of Care™ (standards.vet), a next-generation clinical decision support tool [...]

Tevogen Bio to Receive $8 Million of Non-Dilutive Grant Funding, Reiterates Efficient Operations

03/03/2025 - 18:52

Tevogen Bio will receive the remaining $8 million grant, totaling $10 million, from KRHP LLC this quarter, following a positive review of its progress, particularly in Tevogen.AI. Efficient operations with operating [...]

Full-Year 2024 Results - Progress on the implementation of the FOCUS-27 plan driven by enhanced effectiveness and financial discipline

03/03/2025 - 18:35

Press Release Paris, 3 rd March, 2025 Full-year 2024 results 1 : Operational resilience and strong increase in Free Cash Flow before financing in a challenging environment Net sales down 10.0% to €911.9 million, driven [...]

Résultats 2024 - Progrès dans la mise en œuvre du plan FOCUS-27 soutenue par une efficacité accrue et une discipline financière

03/03/2025 - 18:35

Communiqué de presse Paris, le 3 mars 2025 Résultats 1 de l’exercice 2024 : résilience opérationnelle et forte hausse de la génération de trésorerie avant financement dans un contexte difficile Chiffre d’affaires en [...]

Le schéma thérapeutique à base de DARZALEX® (daratumumab) par voie sous-cutanée de Johnson & Johnson reçoit un avis favorable du CMUH pour les patients atteints d’un myélome multiple nouvellement diagnostiqué, quelle que soit l’éligibilité à la greffe

03/03/2025 - 16:58

S’il est approuvé, le daratumumab sera le seul anti-CD38 disponible pour tous les types de patients atteints d’un myélome multiple nouvellement diagnostiqué, faisant ainsi du daratumumab un traitement fondamental de [...]

Zelluna ASA [ZLNA]: The first ever cell therapy company to list on the Oslo Stock Exchange following successful completion of the business combination and private placement

03/03/2025 - 16:46

Oslo, Norway, 03 March, 2025 - Zelluna ASA, a company pioneering allogeneic ‘off the shelf’ T Cell Receptor based Natural Killer (TCR-NK) cells for the treatment of cancer, today announces the successful completion of a [...]

Health-ISAC Releases Its 2024 Annual Report

03/03/2025 - 16:10

Insights on Achievements in Strengthening Global Health Sector Resilience ORLANDO, Fla., March 03, 2025 (GLOBE NEWSWIRE) -- Health Information Sharing and Analysis Center ( Health-ISAC ), the non-profit industry-led [...]

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

03/03/2025 - 15:30

ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 3 March 2025 at 16.30 EET Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion [...]

IN8bio Announces Advanced Gamma-Delta (γδ) T cell Engager (TCE) Platform for Oncology and Autoimmune Diseases

03/03/2025 - 15:28

Proprietary platform represents the first known approach capable of sustained γδ T cell expansion, eliminating target cells with robust potency INB-619, a next generation γδ TCE targeting CD19, eradicates B cells in [...]

Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis

03/03/2025 - 15:27

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that following a prespecified data review and recommendation by the trial’s independent Data [...]

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

03/03/2025 - 15:15

BASEL, Switzerland and VANCOUVER, British Columbia and WARMINSTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid [...]

Lexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain

02/03/2025 - 22:13

Conference call and webcast at 8:00 a.m. ET on Monday, March 3, 2025 THE WOODLANDS, Texas, March 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will hold a [...]

Merus annonce les résultats financiers de son quatrième trimestre et de l’ensemble de son exercice 2024, et fait le point sur ses activités

02/03/2025 - 02:00

- Inclusion en cours pour les études d’enregistrement de phase III visant l’évaluation du pétosemtamab en association avec le pembrolizumab en traitement de 1ᵉ ligne pour un CETC r/m PD-L1 et l’évaluation du [...]

Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

01/03/2025 - 18:45

REDWOOD CITY, Calif., March 01, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy [...]

Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025

01/03/2025 - 18:45

- Greatly improved patient quality of life and reduced disease impact in patients with CSU and CIndU - - 82% of CSU patients reported that symptoms no longer had an impact on their quality of life at Week 52 - - 60% of [...]

International Myeloma Foundation (IMF) Celebrates Myeloma Milestones for 2025 Myeloma Action Month

01/03/2025 - 14:45

STUDIO CITY, Calif., March 01, 2025 (GLOBE NEWSWIRE) -- Myeloma Action Month is an annual global awareness campaign that takes place every March to raise awareness and inspire action for multiple myeloma—a blood cancer [...]